In this issue:
NIAGARA: perioperative durvalumab with\neoadjuvant chemotherapy in MIBC
AMBASSADOR: adjuvant pembrolizumab in high-risk MIBC after radical cystectomy
TRUCE-02: tislelizumab + low-dose nabpaclitaxel in extensive, very high-risk NMIBC
T-DXd + nivolumab in HER2-expressing metastatic breast/urothelial cancer
Disitamab vedotin + toripalimab in locally advanced/metastatic urothelial carcinoma
TRUCE-01: tislelizumab + low-dose nab-paclitaxel in MIBC
NEXT: nivolumab adjuvant to chemo-radiation in localised MIBC
RETAIN 1: a risk-adapted approach for MIBC
KEYNOTE-361: exploratory analysis of TMB & PD-L1
Improved outcomes with antihistamines during immunotherapy for metastatic urothelial cancer
Download PDF